INTRODUCTION
Driven by technological advances, DNA sequencing has rapidly become an important tool in the diagnosis of genetic disease. Presently, exome sequencing, either using targeted clinical panels or whole exome sequencing, is the predominant approach used in clinical practice. However, whole genome sequencing is likely to increase in use as interpretive tools, and appropriate data sources are developed and cost falls. In response to the integration of sequencing into care and in recognition of its complexity, particularly when used for prenatal diagnosis of fetuses with suspected genetic disorders, the Board of Directors of the International Society for Prenatal Diagnosis (ISPD), the Society for Maternal-Fetal Medicine (SMFM), and the Perinatal Quality Foundation (PQF) have developed these 'points requiring consideration' for practitioners and laboratories offering this service.
Exome sequencing is an emerging technology for the evaluation of the fetus with structural anomalies that are detected on ultrasound. A recent systematic literature review (2014 to 2017) revealed a broad range (6.2-80%) of diagnostic yield in fetuses with structural anomalies. 1 With refinement of testing criteria including trio analysis, a focus on multiple anomalies and use of structured variant curation, the likelihood of a positive finding increases. 1 Along with the implementation of this new technology, there is the need for enhanced understanding and a framework to address patient and health professional education. This testing presents significant challenges, including incidental findings in the parents and/or fetus, impact on family members, and responsibility for future re-analysis. 2 The current literature, including systematic reviews, cohort analyses, policy-guideline reviews, and expert opinions, was examined to support the development of this statement on the use of diagnostic genome-wide sequencing for prenatal diagnosis. We also included elements and comments from a panel discussion at the 21st Annual Conference on Prenatal Diagnosis and Fetal Therapy of the ISPD. While there are 3 billion nucleotides (base pairs) within the 23 chromosomes, only about 1.5% of the genetic information codes for the 20,000 genes in the human genome. A smaller number of disease associated genes (4,000-5,000 identified genes) are termed 'clinical exomes', and these selected genes may be evaluated in certain laboratory settings.
The underlying principle of this document is that the introduction of new genetic technologies into reproductive care must take into account lessons learned from existing prenatal genetic testing, consideration of the impact of innovations, attention to patient and provider education, and consideration of the wider ethical and societal concerns. 1 Using this approach, the authors came to the following consensus opinion on the clinical use of prenatal diagnostic genome wide sequencing including whole exome sequencing, targeted analysis using clinical panels, and whole genome sequencing, hereafter referred to as sequencing:
1. The use of diagnostic sequencing is currently being introduced for evaluation of fetuses for whom standard diagnostic genetic testing, such as chromosomal microarray analysis (CMA), has already been performed and is uninformative or is offered concurrently according to accepted practice guidelines, or for whom expert genetic opinion determines that standard genetic testing is less optimal than sequencing for the presenting fetal phenotype. 2. The routine use of prenatal sequencing as a diagnostic test cannot currently be supported due to insufficient validation data and knowledge about its benefits and pitfalls. [1] [2] [3] validation are needed and when completed may result in confirmation or revision of this position. Currently, it is ideally done in the setting of a research protocol. Alternatively, sequencing may be performed outside a research setting on a case-by-case basis when a genetic disorder is suspected for which a confirmatory genetic diagnosis can be obtained more quickly and accurately by sequencing. Such cases should be managed after consultation with and under the expert guidance of genetic professionals working in multidisciplinary teams with expertise in the clinical diagnostic application of sequencing, including interpretation of genomic sequencing results and how they translate to the prenatal setting, as well as expertise in prenatal imaging and counseling.
Points to consider
It is recommended that for all diagnostic applications of genome-wide sequencing, whether in a research setting or offered clinically, the following important points are considered:
1. Diagnostic sequencing for fetal indications is best done as a trio analysis, where fetal and both parental samples are sequenced and analyzed together. The trio approach currently benefits timeliness of result interpretation and aids assignment of pathogenicity for detected sequence variants. If proband-only sequencing is performed, validation of diagnostic or potentially diagnostic findings best includes a determination of inheritance through targeted testing of samples from biological parents. 2. There is currently limited genotype-phenotype correlation for the genetic disorders identified in the fetal period because ultrasound imaging is frequently limited, and the fetal phenotypes of many conditions have not been well described. It is therefore uncertain if sequencing should focus on a limited panel of genes suspected to be associated with the fetal phenotype or whether a genome-wide approach should be used. It is also uncertain whether interpretation of variants found by genome-wide sequencing should follow the general guidelines for interpretation and reporting of results for children and adults, or whether a more restrictive approach, limited to those variants that explain the phenotype, is preferable in the prenatal setting. 3. The provider or providers who offer sequencing for fetal indications and who conduct the pre-test education and counseling, obtain informed consent, and conduct post-test counseling and result disclosure must have an in-depth understanding of the benefits and risks to the fetus and parents of trio-based sequencing. i. The types of results to be conveyed (variants that are pathogenic, likely pathogenic, of uncertain significance, likely benign, and benign). ii. Realistic expectations about the chance that a clinically significant result will be obtained. iii. The timeframe (range) when a result can be expected. iv. The possibility that no result is obtained (e.g.
related to sample quality), or that a result may not be available before the birth of the fetus in ongoing pregnancies. v. Inclusion or exclusion of incidental findings (e.g. an unexpected childhood disorder) in the results disclosure. vi. Inclusion or exclusion of secondary findings (e.g. cancer-susceptibility genes) in the results disclosure. vii. The handling of discoveries related to adult-onset conditions on fetal samples. viii. The possibility of uncovering non-paternity or close parentage (e.g. consanguinity or an incestuous relationship between the biological parents of the fetus). ix. Result disclosure and post-test counseling will be based on knowledge that is current at the time of result interpretation and disclosure. Potential changes over time are likely to occur in our knowledge of disease genes, pathogenicity of sequence variants and fetal phenotypes. This should include information on available strategies for sample and/or data storage, and re-analysis.
x. The importance of data sharing in de-identified databases (ISPD, SMFM, and PQF endorse the position of the ACMG that laboratory and clinical genomic data sharing is crucial for genetic healthcare). 4 Where this is available, consent should be obtained for storing this data, and parents should be advised of who will have access and for what purpose. f. Post-test counseling and return of results should take into account the documented patient and provider pretest discussions of options and choices including which results will be returned. It is recommended that all individuals undergoing sequencing always receive posttest counseling, including those for whom sequencing has not yielded clinically useful information.
The science and clinical application of fetal diagnostic sequencing is still an evolving field wherein large studies are lacking, and evidence is limited, although rapidly increasing. Early experience supports the following recommendations for laboratories and clinicians offering diagnostic sequencing for fetal indications:
1. Although experience is still limited, the current existing data suggest that the following indications are scenarios where fetal sequencing may be beneficial: a. A current pregnancy with a fetus with a single major anomaly or with multiple organ system anomalies that are suggestive of a possible genetic etiology, but no genetic diagnosis was found after CMA; or in select situations with no CMA result, following a multidisciplinary review and consensus, in which there is a fetus with a multiple anomaly 'pattern' that strongly suggests a single gene disorder. b. A personal (maternal or paternal) history of a prior undiagnosed fetus (or child) affected with a major single anomaly or multiple anomalies suggestive of a genetic etiology, and a recurrence of similar anomalies in the current pregnancy without a genetic diagnosis after karyotype or CMA. In addition, when such parents present for preconception counseling and no sample is available from the affected proband, or if a fetal sample cannot be obtained in an ongoing pregnancy, it is considered appropriate to offer sequencing for both biological parents to look for shared carrier status for autosomal recessive mutations that might explain the fetal phenotype. 5 However, where possible, obtaining tissue from a previous abnormal fetus or child for exome sequencing is preferable. c. In families with a history of recurrent stillbirths of unknown etiology after karyotype and/or CMA, where the fetus in the current pregnancy has a recurrent pattern of anomalies. d. There is currently no evidence that supports routine testing on fetal tissue obtained from an invasive prenatal procedure (amniocentesis, CVS, cordocentesis, other) for indications other than fetal anomalies.
Although evidence is still limited, early experience also supports the following recommendations for diagnostic or research laboratories pertaining to quality standards, variant interpretation, and the return of results:
1. Laboratory quality standards, analysis, and variant annotation principles outlined for other uses of clinical diagnostic sequencing should be followed. As with all diagnostic testing, this should only be performed in accredited diagnostic laboratories with relevant experience in prenatal genomic diagnostic testing and interpretation. 
